Nerve growth factor and its receptor in schizophrenia

BBA Clinical

Volumn 1, Issue , 2014, Pages 24-29

  Zakharyan, Roksana ^a   Atshemyan, Sofi ^a   Gevorgyan, Anaida ^b   Boyajyan, Anna ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Armenia)

^b National Statistical Service of the Republic of Armenia   (Armenia)

Author keywords

Blood levels; Genetic polymorphism; Nerve growth factor; Nerve growth factor receptor; PCR SSP; Schizophrenia

Indexed keywords

HALOPERIDOL; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CELL PLASTICITY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84901987106     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2014.05.001     Document Type: Article

References (61)

1. van Os J., Rutten B.P., Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr. Bull. 2008, 34:1066-1082.
2. Gejman P.V., Sanders A.R., Kendler K.S. Genetics of schizophrenia: new findings and challenges. Annu. Rev. Genomics Hum. Genet. 2011, 12:121-144.
3. Owen M.J., O'Donovan M.C., Thapar A., Craddock N. Neurodevelopmental hypothesis of schizophrenia. Br. J. Psychiatry 2011, 198:173-175.
4. Ashe P.C., Berry M.D., Boulton A.A. Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:691-707.
5. Pérez-Neri I., Ramírez-Bermúdez J., Montes S., Ríos C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem. Res. 2006, 31:1279-1294.
6. Archer T. Neurodegeneration in schizophrenia. Expert. Rev. Neurother. 2010, 10:1131-1141.
7. Lublin H. Cognitive dysfunction in schizophrenia. Acta Psychiatr. Scand. Suppl. 2001, 104:5-9.
8. Matza L.S., Buchanan R., Purdon S., Brewster-Jordan J., Zhao Y., Revicki D.A. Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment. Schizophr. Bull. 2006, 32:666-678.
9. Yin D.M., Chen Y.J., Sathyamurthy A., Xiong W.C., Mei L. Synaptic dysfunction in schizophrenia. Adv. Exp. Med. Biol. 2012, 970:493-516.
10. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008, 9:437-452.
11. Pilato F., Profice P., Ranieri F., Capone F., Di Iorio R., Florio L., Di Lazzaro V. Synaptic plasticity in neurodegenerative diseases evaluated and modulated by in vivo neurophysiological techniques. Mol. Neurobiol. 2012, 46:563-571.
12. Zakharyan R., Boyajyan A., Arakelyan A., Gevorgyan A., Mrazek F., Petrek M. Functional variants of the genes involved in neurodevelopment and susceptibility to schizophrenia in Armenian population. Hum. Immunol. 2011, 72:746-748.
13. Nieto R., Kukuljan M., Silva H. BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front. Psychiatry 2013, 4:45.
14. Stephan K.E., Baldeweg T., Friston K.J. Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatry 2006, 59:929-939.
15. Laske C., Eschweiler G.W. Brain-derived neurotrophic factor: from nerve growth factor to modulator of brain plasticity in cognitive processes and psychiatric diseases. Nervenarzt 2006, 77:523-537.
16. Wiescholleck V., Manahan-Vaughan D. Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis. Neuropharmacology 2013, 74:48-58.
17. Wiescholleck V., Manahan-Vaughan D. Persistent deficits in hippocampal synaptic plasticity accompany losses of hippocampus-dependent memory in a rodent model of psychosis. Front. Integr. Neurosci. 2013, 7:12.
18. McAllister A.K., Katz L.C., Lo D.C. Neurotrophins and synaptic plasticity. Annu. Rev. Neurosci. 1999, 22:295-318.
19. Vega J.A., García-Suárez O., Hannestad J., Pérez-Pérez M., Germanà A. Neurotrophins and the immune system. J. Anat. 2003, 203:1-19.
20. Saetre P., Emilsson L., Axelsson E., Kreuger J., Lindholm E., Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007, 7:46.
21. Boyajyan A., Zakharyan R., Khoyetsyan A. Molecular and genetic indicators of aberrant immunity and apoptosis in schizophrenia. Schizophrenia Research: Recent Advances 2012, Nova Science Publishers Inc., USA, (Chapter XI). T. Sumiyoshi (Ed.).
22. Buckley P.F., Mahadik S., Pillai A., Terry A. Neurotrophins and schizophrenia. Schizophr. Res. 2007, 94:1-11.
23. Stanisz A.M., Stanisz J.A. Nerve growth factor and neuroimmune interactions in inflammatory diseases. Ann. N. Y. Acad. Sci. 2000, 917:268-272.
24. Jockers-Scherubl M.C., Zubraegel D., Baer T., Linden M., Danker-Hopfe H., Schulte-Herbruggen O., Neu P., Hellweg R. Nerve growth factor serum concentrations rise after successful cognitive-behavioural therapy of generalized anxiety disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:200-204.
25. Xiong P., Zeng Y., Zhu Z., Tan D., Xu F., Lu J., Wan J., Ma M. Reduced NGF serum levels and abnormal P300 event-related potential in first episode schizophrenia. Schizophr. Res. 2010, 119:34-39.
26. Xiong P., Zeng Y., Wan J., Xiaohan D.H., Tan D., Lu J., Xu F., Li H.Y., Zhu Z., Ma M. The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res. 2011, 189:72-76.
27. Jockers-Scherubl M.C., Matthies U., Danker-Hopfe H., Lang U.E., Mahlberg R., Hellweg R. Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. J. Psychopharmacol. 2003, 17:439-445.
28. The international statistical classification of diseases and related health problems 1992, World Health Organization, Geneva. 10th ed.
29. Diagnostic and statistical manual of mental disorders. American Psychiatric Association 2000, American Psychiatric Publishing, Arlington (VA), (text revised). forth ed.
30. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition (SCID-I/NP). Biometrics Research 2002, New York State Psychiatric Institute, New York.
31. Sambrook J., Russell D.W. Molecular cloning: a laboratory manual 2001, Cold Spring Harbor Laboratory Press, New York.
32. International HapMap Consortium The International HapMap Project. Nature 2003, 426:789-796. (www.hapmap.org).
33. Bunce M., O'Neil C.M., Barnado M.C., Krausa P., Browning M.J., Morris P.J., Welsh K.I. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB3, DRB4, DRB5&DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers. Tissue Antigens 1995, 46:355-367.
34. Rice T.K., Schork N.J., Rao D.C. Methods for handling multiple testing. Adv. Genet. 2008, 60:293-308.
35. Lalouel J.M., Rohrwasser A. Power and replication in case-control studies. Am. J. Hypertens. 2002, 15:201-205.
36. Syed Z., Dudbridge F., Kent L. An investigation of the neurotrophic factor genes GDNF, NGF, and NT3 in susceptibility to ADHD. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144B:375-378.
37. Di Maria E., Giorgio E., Uliana V., Bonvicini C., Faravelli F., Cammarata S., Novello M.C., Galimberti D., Scarpini E., Zanetti O., Gennarelli M., Tabaton M. Possible influence of a non-synonymous polymorphism located in the NGF precursor on susceptibility to late-onset Alzheimer's disease and mild cognitive impairment. J. Alzheimers Dis. 2012, 29:699-705.
38. Park J.K., Lee S.M., Kang W.S., Kim S.K., Cho A.R. NGF polymorphisms and haplotypes are associated with schizophrenia in Korean population. Mol. Cell Toxicol. 2011, 7:375-380.
39. Aloe L., Calzà L. NGF and related molecules in health and disease. Progress in Brain Research 2004, 146. Elsevier, Amsterdam.
40. Levi-Montalcini R., Skaper S.D., Dal Toso R., Petrelli L., Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 1996, 19:514-520.
41. Bracci-Laudiero L., Aloe L., Levi-Montalcini R., Galeazzi M., Schilter D., Scully J.L., Otten U. Increased levels of NGF in sera of systemic lupus erythematosus patients. Neuroreport 1993, 4:563-565.
42. Alleva E., Francia N. Psychiatric vulnerability: suggestions from animal models and role of neurotrophins. Neurosci. Biobehav. Rev. 2009, 33:525-536.
43. Faradji V., Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol. Scand. 1990, 81:402-406.
44. Bonini S., Lambiase A., Bonini S., Angelucci F., Magrini L., Manni L., Aloe L. Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:10955-10960.
45. Aloe L., Levi-Montalcini R. Nerve growth factor-induced transformation of immature chromaffin cells in vivo into sympathetic neurons: effect of antiserum to nerve growth factor. Proc. Natl. Acad. Sci. U. S. A. 1979, 76:1246-1250.
46. Chen M.G., Chen J.S., Calissano P., Levi-Montalcini R. Nerve growth factor prevents vinblastine destructive effects on sympathetic ganglia in newborn mice. Proc. Natl. Acad. Sci. U. S. A. 1977, 74:5559-5563.
47. Levi-Montalcini R., Aloe L., Mugnaini E., Oesch F., Thoenen H. Nerve growth factor induces volume increase and enhances tyrosine hydroxylase synthesis in chemically axotomized sympathetic ganglia of newborn rats. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:595-599.
48. Levi-Montalcini R. The nerve growth factor: thirty-five years later. EMBO J. 1987, 6:1145-1154.
49. Levi-Montalcini R., Aloe L. Differentiating effects of murine nerve growth factor in the peripheral and central nervous systems of Xenopus laevis tadpoles. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:7111-7115.
50. Spillantini M.G., Aloe L., Alleva E., De Simone R., Goedert M., Levi-Montalcini R. Nerve growth factor mRNA and protein increase in hypothalamus in a mouse model of aggression. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:8555-8559.
51. Aloe L., Alleva E., Böhm A., Levi-Montalcini R. Aggressive behavior induces release of nerve growth factor from mouse salivary gland into the bloodstream. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:6184-6187.
52. Lambiase A., Rama P., Bonini S., Caprifoglio G., Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N. Engl. J. Med. 1998, 338:1174-1180.
53. Bernabei R., Landi F., Bonini S., Onder G., Lambiase A., Pola R., Aloe L. Effect of topical application of nerve-growth factor on pressure ulcers. Lancet 1999, 354:307.
54. Landi F., Aloe L., Russo A., Cesari M., Onder G., Bonini S., Carbonin P., Bernabei R. Topical treatment of pressure ulcers with nerve growth factor: a randomized clinical trial. Ann. Intern. Med. 2003, 139:635-641.
55. Tuveri M., Generini S., Matucci-Cernic M., Aloe L. NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet 2000, 356:1739-1740.
56. Chiaretti A., Piastra M., Caresta E., Nanni L., Aloe L. Improving ischaemic skin revascularisation by nerve growth factor in a child with crush syndrome. Arch. Dis. Child. 2002, 87:446-448.
57. Tuszynski M.H. Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol. 2002, 1:51-57.
58. De Rosa R., Garcia A.A., Braschi C., Capsoni S., Maffei L., Berardi N., Cattaneo A. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3811-3816.
59. Villoslada P., Hauser S.L., Bartke I., Unger J., Heald N., Rosenberg D., Cheung S.W., Mobley W.C., Fisher S., Genain C.P. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J. Exp. Med. 2000, 191:1799-1806.
60. Manca A., Capsoni S., Di Luzio A., Vignone D., Malerba F., Paoletti F., Brandi R., Arisi I., Cattaneo A., Levi-Montalcini R. Nerve growth factor regulates axial rotation during early stages of chick embryo development. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2009-2014.
61. Cheng H.C., Sun Y., Lai L.C., Chen S.Y., Lee W.C., Chen J.H., Chen T.F., Chen H.H., Wen L.L., Yip P.K., Chu Y.M., Chen W.J., Chen Y.C. Genetic polymorphisms of nerve growth factor receptor (NGFR) and the risk of Alzheimer's disease. J. Negat. Results Biomed. 2012, 11:5. 10.1186/1477-5751-11-5.